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Background
Intravenous Immunoglobulin G (IVIg) therapy is widely
used to treat autoimmune diseases. A variety of mechan-
isms have been suggested to be responsible for the anti-
inflammatory activity of IVIg. Among these, terminal sialic
acid residues in the sugar moiety of the IgG Fc-fragment
have been shown to be critical for its anti-inflammatory
activity in a model of serum transfer arthritis. Moreover,
splenic resident cells expressing specific-ICAM3 grabbing
nonintegrin-related1 (SIGNR1) were shown to have the
capacity to bind antibodies rich in sialic acid residues, sug-
gesting a role of the spleen in this immunomodulatory
pathway. Recently, B cells and the sialic acid-binding pro-
tein CD22 were suggested to be involved in the IVIg-
mediated anti-inflammatory process.
Material and methods
To induce a murine model of thrombocytopenia (ITP),
mice were injected with the specific anti-platelet antibody
6A6-IgG2a. Mice were either pretreated with IVIg or PBS
two hours prior to platelet depletion. Splenectomized mice
and several mouse strains lacking B cells, CD22 or
SIGNR1 were used for experiments. Flow cytometric ana-
lysis revealed in vivo binding of human IgG-molecules to
different cell populations in peripheral blood of IVIg trea-
ted mice. Deglycosylation of IVIg preparations was
achieved by enzymatic cleavage with neuraminidase or
PNGaseF.
Results
Mice treated with de-glycosylated IVIg lacking either the
whole sugar moiety or the terminal sialic acid residue
were not protected from ITP. We demonstrated that IVIg
activity was still functional in splenectomized mice but
could be blocked with a specific anti-SIGNR1 antibody.
Despite the capacity of IVIg to recognize sialic acid rich
IgG via CD22 on B cells, neither B cells nor CD22 were
involved in IVIg dependent suppression in autoantibody
induced ITP. Binding efficiency of IVIg to myeloid cells
and leukocytes was neither altered in mice lacking B cells
or CD22 nor in mice treated with de-syalylated IVIg.
Conclusions
These results suggest a spleen-independent but sialic acid-
and SIGNR1-dependent mechanism responsible for IVIg
effects in ITP. Moreover, neither B cells nor CD22 are cri-
tical for the anti-inflammatory activity of IVIg.
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